A Phase 1 interventional study of Tirzepatide and Tirzepatide in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-05.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study has four parts. Each participant will enroll in one part.
Part A: The purpose of Part A is to compare study drug tirzepatide solution formulation to a powder formulation mixed with water and given subcutaneously (SC) (just under the skin). Part A will measure how much of the study drug gets into the blood stream and how long it takes the body to get rid of it.
Part B: The purpose of Part B is to evaluate the safety and tolerability of tirzepatide intravenous (IV) formulation when administered into a vein.
Part C: The purpose of Part C is to evaluate the safety and tolerability of tirzepatide following multiple SC weekly doses of a solution.
Part D: The purpose of Part D is to evaluate the safety and tolerability of tirzepatide following single IV bolus dose of lyophilized formulation.
This study will last approximately 70 days for each part (Part A, Part B or Part D) and 92 days for Part C. This does not include screening. Screening is required within 28 days prior to the start of the study.
Eli Lilly and Company is the lead sponsor of 2,109 studies on the registry; 153 are open to participants now.
Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 5 milligrams (mg) of tirzepatide subcutaneous (SC) solution formulation.
Drug: Tirzepatide
Participants received 5 mg of tirzepatide SC lyophilized formulation.
Drug: Tirzepatide
Participants received Intravenous (IV) infusion of a single 0.5 mg dose of tirzepatide formulation.
Drug: Tirzepatide
Participants received tirzepatide subcutaneous solution at 5 mg on Days 1 (week 1) and 8 (Week 2), 7.5 mg on Day 15 (Week 3) and 10 mg on Day 22 (Week 4).
Drug: Tirzepatide
Participants received SC injection of placebo.
Drug: Placebo
Participants received IV bolus of 0.5 mg tirzepatide lyophilized formulation.
Drug: Tirzepatide
Administered SC
Also known as: LY3298176
Administered IV
Also known as: LY3298176
Administered SC
Administered IV
Also known as: LY3298176
Pharmacokinetics (PK) Part A: Area Under the Concentration Versus Time Curve [AUC (0-∞)] of Tirzepatide
Pharmacokinetics (PK) Part A: Area under the concentration versus time curve \[AUC (0-∞)\] of tirzepatide.
Time frame: Part A: Predose, 8, 12, 24, 48, 72, 96, 120, 144, 168, 336, 480, 816-864 hours postdose
PK Part A: Maximum Observed Drug Concentration (Cmax) of Tirzepatide
PK Part A: Maximum observed plasma drug concentration (Cmax) of tirzepatide.
Time frame: Part A: Predose, 8, 12, 24, 48, 72, 96, 120, 144, 168, 336, 480 and 816-864 hours postdose
PK Part B: Area Under the Concentration Versus Time Curve [AUC (0-∞)] of Tirzepatide
PK Part B: Area under the concentration versus time curve \[AUC (0-∞)\] of tirzepatide.
Time frame: Part B: Predose, 0.08 hours (h), 0.16h, 0.5h, 1h, 2h, 4h, 8h, 12h, 24h, 36h, 48h, 72h, 96h, 120h, 144h, 168h, 336h, 816h-864h and >=70 days post dose
PK Part C: Area Under the Concentration Versus Time Curve [AUC (0-τ)] of Tirzepatide
PK Part C: Area under the concentration versus time curve during one dosing interval (168 hours) \[AUC (0-τ)\] of tirzepatide.
Time frame: Part C: Predose, 8 hours (h) (day (D)1), 24h (D2), 48h (D3),72h (D4), predose (D8), predose (D15), 8h (D15), 24h (D16), 48h (D17), 72h (D18), predose (D22), 8h (D22), 24h (D23), 48h (D24), 72h (D25), D57 and >= D96 postdose
PK Part C: Maximum Observed Drug Concentration (Cmax) of Tirzepatide
PK Part C: Maximum observed plasma drug concentration (Cmax) of tirzepatide.
Time frame: Part C: Predose, 8 hours (h) (day (D)1), 24h (D2), 48h (D3),72h (D4), predose (D8), predose (D15), 8h (D15), 24h (D16), 48h (D17), 72h (D18), predose (D22), 8h (D22), 24h (D23), 48h (D24), 72h (D25), D57 and >= D96 postdose
PK Part D: Area Under the Concentration Versus Time Curve [AUC (0-∞)] of Tirzepatide
PK Part D: Area under the concentration versus time curve \[AUC (0-∞)\] of tirzepatide.
Time frame: Part D: Predose, 0.08 hours (h), 0.16h, 0.5h, 1h, 2h, 4h, 8h, 12h, 24h, 36h, 48h, 72h, 96h, 120h, 144h, 168h, 336h, 816-864h and >= 70 days postdose
4-part study, Part A (2-period, 2-treatment, crossover study with at least 35 days of washout period), Part B (fixed, single-arm treatment study), Part C (placebo-controlled, 4-week dose escalation study) and Part D (a fixed, single-arm treatment study).
| Milestone | Sequence 1-Part A | Sequence 2-Part A | 0.5 mg Tirzepatide IV-Part B | Placebo SC-Part C | 5 mg/7.5 mg/ 10 mg Tirzepatide SC-Part C | 0.5 mg Tirzepatide Bolus IV-Part D |
|---|---|---|---|---|---|---|
| Started | 10 | 10 | 8 | 4 | 12 | 8 |
| Received at least 1 dose of study drug | 10 | 10 | 8 | 4 | 12 | 8 |
| Completed | 10 | 10 | 7 | 4 | 11 | 8 |
| Not completed | 0 | 0 | 1 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 1 | 0 |
| Milestone | Sequence 1-Part A | Sequence 2-Part A | 0.5 mg Tirzepatide IV-Part B | Placebo SC-Part C | 5 mg/7.5 mg/ 10 mg Tirzepatide SC-Part C | 0.5 mg Tirzepatide Bolus IV-Part D |
|---|---|---|---|---|---|---|
| Started | 10 | 10 | 0 | 0 | 0 | 0 |
| Received at least 1 dose of study drug | 10 | 10 | 0 | 0 | 0 | 0 |
| Completed | 9 | 9 | 0 | 0 | 0 | 0 |
| Not completed | 1 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 1 | 0 | 0 | 0 | 0 |
Pharmacokinetics (PK) Part A: Area under the concentration versus time curve \[AUC (0-∞)\] of tirzepatide.
| nanograms*hours per milliliter(ng*hr/mL) | 5 mg Tirzepatide SC (Lyophilized)-Part A | 5 mg Tirzepatide SC (Solution)-Part A |
|---|---|---|
| Pharmacokinetics (PK) Part A: Area Under the Concentration Versus Time Curve [AUC (0-∞)] of Tirzepatide | 113000 ± 19 | 109000 ± 17 |
PK Part A: Maximum observed plasma drug concentration (Cmax) of tirzepatide.
| nanograms per milliliter (ng/mL) | 5 mg Tirzepatide SC (Lyophilized)-Part A | 5 mg Tirzepatide SC (Solution)-Part A |
|---|---|---|
| PK Part A: Maximum Observed Drug Concentration (Cmax) of Tirzepatide | 524 ± 27 | 575 ± 22 |
PK Part B: Area under the concentration versus time curve \[AUC (0-∞)\] of tirzepatide.
| ng*hr/mL | 0.5 mg Tirzepatide IV-Part B |
|---|---|
| PK Part B: Area Under the Concentration Versus Time Curve [AUC (0-∞)] of Tirzepatide | 6680 ± 26 |
PK Part C: Area under the concentration versus time curve during one dosing interval (168 hours) \[AUC (0-τ)\] of tirzepatide.
| ng*hr/mL | 5 mg Tirzepatide SC-Part C | 7.5 mg Tirzepatide SC-Part C | 10 mg Tirzepatide SC-Part C |
|---|---|---|---|
| PK Part C: Area Under the Concentration Versus Time Curve [AUC (0-τ)] of Tirzepatide | 68900 ± 19 | 149000 ± 26 | — |
PK Part C: Maximum observed plasma drug concentration (Cmax) of tirzepatide.
| ng/mL | 5 mg Tirzepatide SC-Part C | 7.5 mg LY3298176 SC-Part C | 10 mg Tirzepatide SC-Part C |
|---|---|---|---|
| PK Part C: Maximum Observed Drug Concentration (Cmax) of Tirzepatide | 663 ± 23 | 1270 ± 24 | 1900 ± 24 |
PK Part D: Area under the concentration versus time curve \[AUC (0-∞)\] of tirzepatide.
| ng*hr/mL | 0.5 mg Tirzepatide Bolus IV-Part D |
|---|---|
| PK Part D: Area Under the Concentration Versus Time Curve [AUC (0-∞)] of Tirzepatide | 14000 ± 16 |
Collected over Up To 92 Days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 5 mg Tirzepatide SC (Lyophilized)-Part A | 0/20 (0%) | 0/20 (0%) | 9/20 (45%) |
| 5 mg Tirzepatide SC (Solution)-Part A | 0/20 (0%) | 0/20 (0%) | 5/20 (25%) |
| 0.5 mg Tirzepatide IV-Part B | 0/8 (0%) | 0/8 (0%) | 1/8 (12.5%) |
| Placebo SC-Part C | 0/4 (0%) | 0/4 (0%) | 1/4 (25%) |
| 5 mg Tirzepatide SC, First-Part C | 0/12 (0%) | 0/12 (0%) | 4/12 (33.3%) |
| 5 mg Tirzepatide SC, Second Dose-Part C | 0/12 (0%) | 0/12 (0%) | 2/12 (16.7%) |
| 7.5 mg LY3298176 SC-Part C | 0/12 (0%) | 0/12 (0%) | 6/12 (50%) |
| 10 mg Tirzepatide SC-Part C | 0/11 (0%) | 0/11 (0%) | 4/11 (36.4%) |
| 0.5 mg Tirzepatide Bolus IV-Part D | 0/8 (0%) | 0/8 (0%) | 3/8 (37.5%) |
| Event | 5 mg Tirzepatide SC (Lyophilized)-Part A | 5 mg Tirzepatide SC (Solution)-Part A | 0.5 mg Tirzepatide IV-Part B | Placebo SC-Part C | 5 mg Tirzepatide SC, First-Part C | 5 mg Tirzepatide SC, Second Dose-Part C | 7.5 mg LY3298176 SC-Part C | 10 mg Tirzepatide SC-Part C | 0.5 mg Tirzepatide Bolus IV-Part D |
|---|---|---|---|---|---|---|---|---|---|
| Injection site reactionGeneral disorders | 5/20 | 2/20 | 0/8 | 0/4 | 0/12 | 0/12 | 2/12 | 3/11 | 0/8 |
| HeadacheNervous system disorders | 1/20 | 0/20 | 0/8 | 1/4 | 0/12 | 0/12 | 0/12 | 3/11 | 0/8 |
| NauseaGastrointestinal disorders | 4/20 | 2/20 | 0/8 | 0/4 | 2/12 | 0/12 | 3/12 | 1/11 | 0/8 |
| Abdominal painGastrointestinal disorders | 2/20 | 3/20 | 0/8 | 0/4 | 0/12 | 1/12 | 2/12 | 1/11 | 0/8 |
| DizzinessNervous system disorders | 0/20 | 0/20 | 0/8 | 0/4 | 0/12 | 0/12 | 2/12 | 0/11 | 0/8 |
| DiarrhoeaGastrointestinal disorders | 3/20 | 1/20 | 0/8 | 0/4 | 0/12 | 0/12 | 1/12 | 0/11 | 0/8 |
| DysphagiaGastrointestinal disorders | 0/20 | 0/20 | 0/8 | 0/4 | 0/12 | 0/12 | 0/12 | 0/11 | 1/8 |
| OdynophagiaGastrointestinal disorders | 0/20 | 0/20 | 0/8 | 0/4 | 0/12 | 0/12 | 0/12 | 0/11 | 1/8 |
| ToothacheGastrointestinal disorders | 0/20 | 0/20 | 0/8 | 0/4 | 0/12 | 0/12 | 0/12 | 0/11 | 1/8 |
| GastroenteritisInfections and infestations | 0/20 | 0/20 | 1/8 | 0/4 | 0/12 | 0/12 | 1/12 | 0/11 | 0/8 |
All randomized participants
| Age, Categorical(Participants) | Sequence 1-Part A | Sequence 2-Part A | 0.5 mg Tirzepatide IV-Part B | Placebo SC-Part C | 5 mg/7.5 mg/ 10 mg Tirzepatide SC-Part C | 0.5 mg Tirzepatide Bolus IV-Part D | Total |
|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 10 | 10 | 8 | 4 | 11 | 8 | 51 |
| >=65 years | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Sex: Female, Male(Participants) | Sequence 1-Part A | Sequence 2-Part A | 0.5 mg Tirzepatide IV-Part B | Placebo SC-Part C | 5 mg/7.5 mg/ 10 mg Tirzepatide SC-Part C | 0.5 mg Tirzepatide Bolus IV-Part D | Total |
|---|---|---|---|---|---|---|---|
| Female | 2 | 2 | 0 | 0 | 7 | 4 | 15 |
| Male | 8 | 8 | 8 | 4 | 5 | 4 | 37 |
| Ethnicity (NIH/OMB)(Participants) | Sequence 1-Part A | Sequence 2-Part A | 0.5 mg Tirzepatide IV-Part B | Placebo SC-Part C | 5 mg/7.5 mg/ 10 mg Tirzepatide SC-Part C | 0.5 mg Tirzepatide Bolus IV-Part D | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 3 | 1 | 1 | 1 | 1 | 2 | 9 |
| Not Hispanic or Latino | 7 | 9 | 7 | 3 | 11 | 6 | 43 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Sequence 1-Part A | Sequence 2-Part A | 0.5 mg Tirzepatide IV-Part B | Placebo SC-Part C | 5 mg/7.5 mg/ 10 mg Tirzepatide SC-Part C | 0.5 mg Tirzepatide Bolus IV-Part D | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 | 0 | 0 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 5 | 7 | 3 | 2 | 8 | 4 | 29 |
| White | 5 | 2 | 4 | 2 | 4 | 3 | 20 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Sequence 1-Part A | Sequence 2-Part A | 0.5 mg Tirzepatide IV-Part B | Placebo SC-Part C | 5 mg/7.5 mg/ 10 mg Tirzepatide SC-Part C | 0.5 mg Tirzepatide Bolus IV-Part D | Total |
|---|---|---|---|---|---|---|---|
| United States | 10 | 10 | 8 | 4 | 12 | 8 | 52 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2017 to primary completion in Dec 2018, 12 months.
Results were first posted in Feb 2024, 5 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tirzepatide